83
Participants
Start Date
November 20, 2018
Primary Completion Date
November 24, 2020
Study Completion Date
November 24, 2020
Sarilumab SAR153191
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Sarilumab matching placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Prednisone
Pharmaceutical form: tablets or capsules Route of administration: oral administration
Prednisone matching placebo
Pharmaceutical form: capsules Route of administration: oral administration
Investigational Site Number 7050001, Ljubljana
Investigational Site Number 0360001, Kogarah
Investigational Site Number 0560001, Leuven
Investigational Site Number 0360003, Camberwell
Investigational Site Number 0360006, Clayton
Investigational Site Number 3480001, Debrecen
Investigational Site Number 2080003, Svendborg
Investigational Site Number 2080002, Aarhus C
Investigational Site Number 7560002, Sankt Gallen
Investigational Site Number 1910001, Zagreb
Investigational Site Number 2760001, Berlin
Investigational Site Number 2330001, Tallinn
Investigational Site Number 7240011, A Coruña
Investigational Site Number 8400019, Philadelphia
Investigational Site Number 3800005, Rozzano
Investigational Site Number 3800001, Milan
Investigational Site Number 7240014, Madrid
Investigational Site Number 2500005, Brest
Investigational Site Number 8400017, Gainesville
Investigational Site Number 8400002, Boca Raton
Investigational Site Number 2500006, Pessac
Investigational Site Number 2500003, Montpellier
Investigational Site Number 3760004, Haifa
Investigational Site Number 7240015, Santa Cruz de Tenerife
Investigational Site Number 7240010, Bilbao
Investigational Site Number 8400014, Iowa City
Investigational Site Number 2500007, Mulhouse
Investigational Site Number 2760007, Tübingen
Investigational Site Number 2760003, Kirchheim unter Teck
Investigational Site Number 2500001, Paris
Investigational Site Number 8400011, Dallas
Investigational Site Number 2500002, Montivilliers
Investigational Site Number 3760006, Ashkelon
Investigational Site Number 2760004, München
Investigational Site Number 8400018, Portland
Investigational Site Number 6430002, Moscow
Investigational Site Number 6430003, Moscow
Investigational Site Number 6430005, Kemerovo
Investigational Site Number 0320001, Buenos Aires
Investigational Site Number 0320002, Caba
Investigational Site Number 1240007, Hamilton
Investigational Site Number 1240010, Montreal
Investigational Site Number 1240001, Rimouski
Investigational Site Number 1240005, Sherbrooke
Investigational Site Number 1240003, Trois-Rivières
Investigational Site Number 2760002, Dresden
Investigational Site Number 5280005, Leeuwarden
Investigational Site Number 5280009, Sittard-Geleen
Investigational Site Number 5280007, The Hague
Investigational Site Number 5280001, Venlo
Investigational Site Number 6200001, Almada
Investigational Site Number 6200005, Aveiro
Investigational Site Number 6200004, Ponte de Lima
Investigational Site Number 7240016, Sabadell
Investigational Site Number 7520003, Örebro
Investigational Site Number 7520001, Uppsala
Investigational Site Number 8260006, Aberdeen
Investigational Site Number 8260004, Gateshead
Investigational Site Number 8260003, Leeds
Investigational Site Number 8260005, Manchester
Investigational Site Number 8260011, Portsmouth
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY